slide deck (pdf) - CME Outfitters
slide deck (pdf) - CME Outfitters slide deck (pdf) - CME Outfitters
Clinical Management Step 4: Referral For the patient with symptoms and bother who is refractory to therapy ! Alpha blockers, PDE5is, antimuscarinics and β3 agonists work quickly. ! 5 ARIs work slowly ! Failure to respond in a reasonable amount of time warrants reevaluation and possible referral Rosenberg MT, et al. Int J Clin Pract. 2010; 64(4):488-496. PMID: 20039975. Rosenberg MT, et al. Publication Pending.
Clinical Connections: Summary ! Treatment of LUTS-BPH should be a patient-centered, shared decision process ! There appears to be a shared pathophysiology that underlies benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) ! Pharmacotherapy of BPH-LUTS and ED takes place in a stepwise algorithm that depends on symptom severity. ! Diagnosis and treatment plans in accordance with the American Urological Association recommendations can improve the management of patients with BPH and ED
- Page 17 and 18: In what percentage of your patients
- Page 19 and 20: Function of the Prostate Normal Fun
- Page 21 and 22: Benign Prostatic Hyperplasia ! A co
- Page 23 and 24: Predominant Symptoms ! The enlarged
- Page 25 and 26: Definition of OAB International Con
- Page 27 and 28: How to differentiate the etiology o
- Page 29 and 30: Common Comorbidities in BPH-LUTS Co
- Page 31 and 32: Audience Response Question Fact: ED
- Page 33 and 34: BPH-LUTS and ED Common Pathophysiol
- Page 35 and 36: What to Keep in Mind in the Evaluat
- Page 37 and 38: The Evaluation of LUTS: History, Ph
- Page 39 and 40: Medications Can Cause or Exacerbate
- Page 41 and 42: Laboratory Tests ! Urinalysis ! Inf
- Page 43 and 44: Audience Response Question The most
- Page 45 and 46: The Purpose of the Voiding Diary !
- Page 47 and 48: Rosenberg MT, et al. Publication Pe
- Page 49 and 50: STEP 1: Informed Surveillance If th
- Page 51 and 52: Clinical Management Step2a: Alpha B
- Page 53 and 54: Clinical Management Step2b: Phospho
- Page 55 and 56: Rosenberg MT, et al. Publication Pe
- Page 57 and 58: Antimuscarinics - Immediate Release
- Page 59 and 60: ! Dry Mouth ! Constipation ! Headac
- Page 61 and 62: Beta 3 Agonists Drug Mirabegron Dos
- Page 63 and 64: Clinical Management Step3b: Adding
- Page 65 and 66: 5 Alpha Reductase Inhibitors (5ARI)
- Page 67: Rosenberg MT, et al. Publication Pe
Clinical Connections: Summary<br />
! Treatment of LUTS-BPH should be a patient-centered, shared<br />
decision process<br />
! There appears to be a shared pathophysiology that underlies<br />
benign prostatic hyperplasia (BPH) and erectile dysfunction<br />
(ED)<br />
! Pharmacotherapy of BPH-LUTS and ED takes place in a stepwise<br />
algorithm that depends on symptom severity.<br />
! Diagnosis and treatment plans in accordance with the American<br />
Urological Association recommendations can improve the<br />
management of patients with BPH and ED
Change language